These companies were recognized Wednesday by Fast Company as the most innovative companies in the industry.
News & Features
Seven key events helped transform and redefine the MIGS space into one of the hottest sectors in medtech.
Indiana University of Medicine researchers said the test can help identify biomarkers in the blood and could actually help in the fight against opioid abuse.
These tweets about medical devices and health conditions are proof that sometimes laughter really is the best medicine.
Tandem Diabetes Care has received a nod from FDA for the t:slim X2 insulin pump and the approval opens up a new device category – Alternate Controller Enabled Infusion Pumps.
Medtech was definitely hot for M&A last year, but will that trend will continue in 2019? Here's what the biggest players in the industry said about M&A during recent earnings calls.
The Salt Lake City-based company said its Tria device is one of the first biopolymer heart valve platforms.
Hackers have already demanded ransom for removing sensitive patient data. Could your product foil future attacks?
The John Wayne Cancer Institute in Santa Monica, CA and Maimonides Medical Center in Brooklyn, NY were the first two hospitals to adopt EDAP TMS’ new Focal One device — an advanced ultrasound technology that can be used to target and ablate diseased tissue.
Iota Biosciences has raised about $15 million in a series A round to help further develop its millimeter-sized neural dust platform.
The company has had significant struggles with the EndoBarrier in the past, but a nod from FDA and the IRB to begin a new pivotal trial might be step back in the right direction for the technology.
The definition of a biomaterial has evolved over time, but given today's efforts to better characterize medical device biocompatibility, is a catch-all term for some materials misleading?
NuVasive has been in the news this week after it was reported that Smith & Nephew was interested in acquiring the company for more than $3 billion. Neither company has officially commented on the rumored deal.